ID   SERC_HUMAN              Reviewed;         370 AA.
AC   Q9Y617; Q5T7G5; Q5T7G6; Q96AW2; Q9BQ12;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2002, sequence version 2.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Phosphoserine aminotransferase;
DE            EC=2.6.1.52;
DE   AltName: Full=Phosphohydroxythreonine aminotransferase;
DE            Short=PSAT;
GN   Name=PSAT1; Synonyms=PSA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=12633500; DOI=10.1042/BJ20030144;
RA   Baek J.Y., Jun Y.D., Taub D., Kim Y.H.;
RT   "Characterization of human phosphoserine aminotransferase involved in
RT   the phosphorylated pathway of L-serine biosynthesis.";
RL   Biochem. J. 373:191-200(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung, Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   BIOPHYSICOCHEMICAL PROPERTIES, INVOLVEMENT IN PSATD, VARIANT PSATD
RP   ALA-100, AND CHARACTERIZATION OF VARIANT PSATD ALA-100.
RX   PubMed=17436247; DOI=10.1086/517888;
RA   Hart C.E., Race V., Achouri Y., Wiame E., Sharrard M., Olpin S.E.,
RA   Watkinson J., Bonham J.R., Jaeken J., Matthijs G., Van Schaftingen E.;
RT   "Phosphoserine aminotransferase deficiency: a novel disorder of the
RT   serine biosynthesis pathway.";
RL   Am. J. Hum. Genet. 80:931-937(2007).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-51; LYS-269; LYS-318;
RP   LYS-323 AND LYS-333, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-331, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   INVOLVEMENT IN NLS2, AND VARIANTS NLS2 VAL-99 AND LEU-179.
RX   PubMed=25152457; DOI=10.1016/j.ajhg.2014.07.012;
RA   Acuna-Hidalgo R., Schanze D., Kariminejad A., Nordgren A.,
RA   Kariminejad M.H., Conner P., Grigelioniene G., Nilsson D.,
RA   Nordenskjold M., Wedell A., Freyer C., Wredenberg A., Wieczorek D.,
RA   Gillessen-Kaesbach G., Kayserili H., Elcioglu N., Ghaderi-Sohi S.,
RA   Goodarzi P., Setayesh H., van de Vorst M., Steehouwer M., Pfundt R.,
RA   Krabichler B., Curry C., MacKenzie M.G., Boycott K.M., Gilissen C.,
RA   Janecke A.R., Hoischen A., Zenker M.;
RT   "Neu-Laxova syndrome is a heterogeneous metabolic disorder caused by
RT   defects in enzymes of the L-serine biosynthesis pathway.";
RL   Am. J. Hum. Genet. 95:285-293(2014).
CC   -!- FUNCTION: Catalyzes the reversible conversion of 3-
CC       phosphohydroxypyruvate to phosphoserine and of 3-hydroxy-2-oxo-4-
CC       phosphonooxybutanoate to phosphohydroxythreonine.
CC       {ECO:0000250|UniProtKB:P10658}.
CC   -!- CATALYTIC ACTIVITY: O-phospho-L-serine + 2-oxoglutarate = 3-
CC       phosphonooxypyruvate + L-glutamate.
CC   -!- CATALYTIC ACTIVITY: 4-phosphonooxy-L-threonine + 2-oxoglutarate =
CC       (3R)-3-hydroxy-2-oxo-4-phosphonooxybutanoate + L-glutamate.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000250};
CC       Note=Binds 1 pyridoxal phosphate per subunit. {ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5 uM for phosphoserine {ECO:0000269|PubMed:17436247};
CC         Vmax=1.35 umol/min/mg enzyme {ECO:0000269|PubMed:17436247};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-serine biosynthesis; L-serine
CC       from 3-phospho-D-glycerate: step 2/3.
CC   -!- PATHWAY: Cofactor biosynthesis; pyridoxine 5'-phosphate
CC       biosynthesis; pyridoxine 5'-phosphate from D-erythrose 4-
CC       phosphate: step 3/5.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=Q9Y617-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta;
CC         IsoId=Q9Y617-2; Sequence=VSP_000237;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in the brain, liver,
CC       kidney and pancreas, and very weakly expressed in the thymus,
CC       prostate, testis and colon.
CC   -!- DISEASE: Phosphoserine aminotransferase deficiency (PSATD)
CC       [MIM:610992]: Characterized biochemically by low plasma and
CC       cerebrospinal fluid concentrations of serine and glycine and
CC       clinically by intractable seizures, acquired microcephaly,
CC       hypertonia, and psychomotor retardation.
CC       {ECO:0000269|PubMed:17436247}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Neu-Laxova syndrome 2 (NLS2) [MIM:616038]: A form of Neu-
CC       Laxova syndrome, a lethal, autosomal recessive multiple
CC       malformation syndrome characterized by ichthyosis, marked
CC       intrauterine growth restriction, microcephaly, short neck, limb
CC       deformities, hypoplastic lungs, edema, and central nervous system
CC       anomalies. These include lissencephaly, cerebellar hypoplasia
CC       and/or abnormal/agenesis of the corpus callosum. Abnormal facial
CC       features include severe proptosis with ectropion, hypertelorism,
CC       micrognathia, flattened nose, and malformed ears.
CC       {ECO:0000269|PubMed:25152457}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the class-V pyridoxal-phosphate-dependent
CC       aminotransferase family. SerC subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF113132; AAD42052.1; -; mRNA.
DR   EMBL; AY131232; AAN71736.1; -; mRNA.
DR   EMBL; BT006840; AAP35486.1; -; mRNA.
DR   EMBL; AL353594; CAI16882.1; -; Genomic_DNA.
DR   EMBL; AL353594; CAI16883.1; -; Genomic_DNA.
DR   EMBL; CH471089; EAW62621.1; -; Genomic_DNA.
DR   EMBL; CH471089; EAW62617.1; -; Genomic_DNA.
DR   EMBL; BC000971; AAH00971.1; -; mRNA.
DR   EMBL; BC004863; AAH04863.1; -; mRNA.
DR   EMBL; BC016645; AAH16645.1; -; mRNA.
DR   EMBL; BC018129; AAH18129.1; -; mRNA.
DR   CCDS; CCDS6659.1; -. [Q9Y617-2]
DR   CCDS; CCDS6660.1; -. [Q9Y617-1]
DR   RefSeq; NP_066977.1; NM_021154.4. [Q9Y617-2]
DR   RefSeq; NP_478059.1; NM_058179.3. [Q9Y617-1]
DR   UniGene; Hs.494261; -.
DR   PDB; 3E77; X-ray; 2.50 A; A/B/C=17-370.
DR   PDBsum; 3E77; -.
DR   ProteinModelPortal; Q9Y617; -.
DR   SMR; Q9Y617; -.
DR   BioGrid; 119001; 37.
DR   IntAct; Q9Y617; 3.
DR   MINT; MINT-1490243; -.
DR   STRING; 9606.ENSP00000365773; -.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   iPTMnet; Q9Y617; -.
DR   PhosphoSitePlus; Q9Y617; -.
DR   SwissPalm; Q9Y617; -.
DR   DMDM; 20141815; -.
DR   REPRODUCTION-2DPAGE; IPI00001734; -.
DR   EPD; Q9Y617; -.
DR   PaxDb; Q9Y617; -.
DR   PeptideAtlas; Q9Y617; -.
DR   PRIDE; Q9Y617; -.
DR   DNASU; 29968; -.
DR   Ensembl; ENST00000347159; ENSP00000317606; ENSG00000135069. [Q9Y617-2]
DR   Ensembl; ENST00000376588; ENSP00000365773; ENSG00000135069. [Q9Y617-1]
DR   GeneID; 29968; -.
DR   KEGG; hsa:29968; -.
DR   UCSC; uc004ala.5; human. [Q9Y617-1]
DR   CTD; 29968; -.
DR   DisGeNET; 29968; -.
DR   GeneCards; PSAT1; -.
DR   HGNC; HGNC:19129; PSAT1.
DR   HPA; CAB014882; -.
DR   HPA; CAB040567; -.
DR   HPA; HPA042924; -.
DR   MalaCards; PSAT1; -.
DR   MIM; 610936; gene.
DR   MIM; 610992; phenotype.
DR   MIM; 616038; phenotype.
DR   neXtProt; NX_Q9Y617; -.
DR   OpenTargets; ENSG00000135069; -.
DR   Orphanet; 2671; Neu-Laxova syndrome.
DR   Orphanet; 284417; Phosphoserine aminotransferase deficiency.
DR   PharmGKB; PA128395782; -.
DR   eggNOG; KOG2790; Eukaryota.
DR   eggNOG; COG1932; LUCA.
DR   GeneTree; ENSGT00390000015177; -.
DR   HOGENOM; HOG000088965; -.
DR   HOVERGEN; HBG001218; -.
DR   InParanoid; Q9Y617; -.
DR   KO; K00831; -.
DR   OMA; GAQKNMG; -.
DR   OrthoDB; EOG091G0964; -.
DR   PhylomeDB; Q9Y617; -.
DR   TreeFam; TF312975; -.
DR   BioCyc; MetaCyc:HS05946-MONOMER; -.
DR   BRENDA; 2.6.1.52; 2681.
DR   Reactome; R-HSA-977347; Serine biosynthesis.
DR   UniPathway; UPA00135; UER00197.
DR   UniPathway; UPA00244; UER00311.
DR   ChiTaRS; PSAT1; human.
DR   EvolutionaryTrace; Q9Y617; -.
DR   GeneWiki; PSAT1; -.
DR   GenomeRNAi; 29968; -.
DR   PRO; PR:Q9Y617; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000135069; -.
DR   CleanEx; HS_PSAT1; -.
DR   ExpressionAtlas; Q9Y617; baseline and differential.
DR   Genevisible; Q9Y617; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0004648; F:O-phospho-L-serine:2-oxoglutarate aminotransferase activity; IBA:GO_Central.
DR   GO; GO:0006564; P:L-serine biosynthetic process; IBA:GO_Central.
DR   GO; GO:0008615; P:pyridoxine biosynthetic process; NAS:UniProtKB.
DR   CDD; cd00611; PSAT_like; 1.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   HAMAP; MF_00160; SerC_aminotrans_5; 1.
DR   InterPro; IPR000192; Aminotrans_V_dom.
DR   InterPro; IPR020578; Aminotrans_V_PyrdxlP_BS.
DR   InterPro; IPR022278; Pser_aminoTfrase.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   Pfam; PF00266; Aminotran_5; 1.
DR   PIRSF; PIRSF000525; SerC; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
DR   TIGRFAMs; TIGR01364; serC_1; 1.
DR   PROSITE; PS00595; AA_TRANSFER_CLASS_5; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Amino-acid biosynthesis; Aminotransferase; Complete proteome;
KW   Disease mutation; Phosphoprotein; Polymorphism; Pyridoxal phosphate;
KW   Reference proteome; Serine biosynthesis; Transferase.
FT   CHAIN         1    370       Phosphoserine aminotransferase.
FT                                /FTId=PRO_0000150135.
FT   REGION       79     80       Pyridoxal phosphate binding.
FT                                {ECO:0000250}.
FT   REGION      241    242       Pyridoxal phosphate binding.
FT                                {ECO:0000250}.
FT   BINDING      45     45       L-glutamate. {ECO:0000250}.
FT   BINDING     107    107       Pyridoxal phosphate. {ECO:0000250}.
FT   BINDING     156    156       Pyridoxal phosphate. {ECO:0000250}.
FT   BINDING     176    176       Pyridoxal phosphate. {ECO:0000250}.
FT   BINDING     199    199       Pyridoxal phosphate. {ECO:0000250}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      51     51       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     127    127       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q99K85}.
FT   MOD_RES     200    200       N6-(pyridoxal phosphate)lysine.
FT                                {ECO:0000250}.
FT   MOD_RES     269    269       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     318    318       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     323    323       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     331    331       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     333    333       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ     291    336       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12633500,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000237.
FT   VARIANT      87     87       P -> A (in dbSNP:rs11540974).
FT                                /FTId=VAR_048235.
FT   VARIANT      99     99       A -> V (in NLS2; dbSNP:rs587777778).
FT                                {ECO:0000269|PubMed:25152457}.
FT                                /FTId=VAR_072571.
FT   VARIANT     100    100       D -> A (in PSATD; reduced Vmax;
FT                                dbSNP:rs118203967).
FT                                {ECO:0000269|PubMed:17436247}.
FT                                /FTId=VAR_037252.
FT   VARIANT     179    179       S -> L (in NLS2; dbSNP:rs587777777).
FT                                {ECO:0000269|PubMed:25152457}.
FT                                /FTId=VAR_072572.
FT   CONFLICT     40     40       L -> V (in Ref. 5; AAH16645).
FT                                {ECO:0000305}.
FT   HELIX        19     27       {ECO:0000244|PDB:3E77}.
FT   STRAND       29     31       {ECO:0000244|PDB:3E77}.
FT   HELIX        32     34       {ECO:0000244|PDB:3E77}.
FT   STRAND       35     37       {ECO:0000244|PDB:3E77}.
FT   TURN         39     41       {ECO:0000244|PDB:3E77}.
FT   HELIX        47     64       {ECO:0000244|PDB:3E77}.
FT   STRAND       70     77       {ECO:0000244|PDB:3E77}.
FT   HELIX        78     90       {ECO:0000244|PDB:3E77}.
FT   HELIX        91     93       {ECO:0000244|PDB:3E77}.
FT   STRAND       98    101       {ECO:0000244|PDB:3E77}.
FT   HELIX       106    115       {ECO:0000244|PDB:3E77}.
FT   TURN        116    118       {ECO:0000244|PDB:3E77}.
FT   STRAND      119    123       {ECO:0000244|PDB:3E77}.
FT   STRAND      129    131       {ECO:0000244|PDB:3E77}.
FT   HELIX       137    139       {ECO:0000244|PDB:3E77}.
FT   STRAND      149    155       {ECO:0000244|PDB:3E77}.
FT   TURN        156    159       {ECO:0000244|PDB:3E77}.
FT   STRAND      173    176       {ECO:0000244|PDB:3E77}.
FT   TURN        178    182       {ECO:0000244|PDB:3E77}.
FT   HELIX       188    190       {ECO:0000244|PDB:3E77}.
FT   STRAND      192    197       {ECO:0000244|PDB:3E77}.
FT   TURN        198    202       {ECO:0000244|PDB:3E77}.
FT   STRAND      208    213       {ECO:0000244|PDB:3E77}.
FT   HELIX       226    228       {ECO:0000244|PDB:3E77}.
FT   HELIX       230    234       {ECO:0000244|PDB:3E77}.
FT   TURN        235    238       {ECO:0000244|PDB:3E77}.
FT   HELIX       245    260       {ECO:0000244|PDB:3E77}.
FT   HELIX       263    283       {ECO:0000244|PDB:3E77}.
FT   STRAND      288    290       {ECO:0000244|PDB:3E77}.
FT   HELIX       295    297       {ECO:0000244|PDB:3E77}.
FT   STRAND      300    309       {ECO:0000244|PDB:3E77}.
FT   HELIX       314    326       {ECO:0000244|PDB:3E77}.
FT   STRAND      329    331       {ECO:0000244|PDB:3E77}.
FT   TURN        336    338       {ECO:0000244|PDB:3E77}.
FT   STRAND      340    344       {ECO:0000244|PDB:3E77}.
FT   HELIX       351    368       {ECO:0000244|PDB:3E77}.
SQ   SEQUENCE   370 AA;  40423 MW;  BAF9A10E71B165B4 CRC64;
     MDAPRQVVNF GPGPAKLPHS VLLEIQKELL DYKGVGISVL EMSHRSSDFA KIINNTENLV
     RELLAVPDNY KVIFLQGGGC GQFSAVPLNL IGLKAGRCAD YVVTGAWSAK AAEEAKKFGT
     INIVHPKLGS YTKIPDPSTW NLNPDASYVY YCANETVHGV EFDFIPDVKG AVLVCDMSSN
     FLSKPVDVSK FGVIFAGAQK NVGSAGVTVV IVRDDLLGFA LRECPSVLEY KVQAGNSSLY
     NTPPCFSIYV MGLVLEWIKN NGGAAAMEKL SSIKSQTIYE IIDNSQGFYV CPVEPQNRSK
     MNIPFRIGNA KGDDALEKRF LDKALELNML SLKGHRSVGG IRASLYNAVT IEDVQKLAAF
     MKKFLEMHQL
//
